Journal: Cancers

Article Title: Machine Learning of Multi-Modal Tumor Imaging Reveals Trajectories of Response to Precision Treatment

doi: 10.3390/cancers15061751

Figure Lengend Snippet: Database generation process. Mice in the training group were divided into two groups: sunitinib-treated and sham-treated. Eight mice from each group were scanned with PETRUS before and after 1, 2, and 3 weeks of treatment. Sinitinib-treated mice were also imaged at 4, 5, and 6 weeks of treatment. Mice of the independent validation set were sunitinib-treated and scanned at baseline and at weeks: 1, 3, and 6 of the treatment.

Article Snippet: The sunitinib group received sunitinib malate (Clinisciences, A10880-500) daily at a dose of 50 mg/kg body weight for 6 consecutive weeks, administered by oral gavage of 200 µL in a 10 mg/mL DMSO/PBS (1:4) solution.

Techniques:

Journal: Cancers

Article Title: Machine Learning of Multi-Modal Tumor Imaging Reveals Trajectories of Response to Precision Treatment

doi: 10.3390/cancers15061751

Figure Lengend Snippet: Evolutionary path of sunitinib-treated mice of the training set. Items marked as * indicate missing classification due to the absence of corresponding PETRUS data. Clusters that were assigned by the RF model are underlined.

Article Snippet: The sunitinib group received sunitinib malate (Clinisciences, A10880-500) daily at a dose of 50 mg/kg body weight for 6 consecutive weeks, administered by oral gavage of 200 µL in a 10 mg/mL DMSO/PBS (1:4) solution.

Techniques:

Journal: Cancers

Article Title: Machine Learning of Multi-Modal Tumor Imaging Reveals Trajectories of Response to Precision Treatment

doi: 10.3390/cancers15061751

Figure Lengend Snippet: Clusterization of the 11 sunitinib mice from the validation group. Items marked as - indicate that the RF approach was unable to assign the record to one any of the A t , B 1 t , B 2 t , C t clusters. Items marked as * indicate no PETRUS data available.

Article Snippet: The sunitinib group received sunitinib malate (Clinisciences, A10880-500) daily at a dose of 50 mg/kg body weight for 6 consecutive weeks, administered by oral gavage of 200 µL in a 10 mg/mL DMSO/PBS (1:4) solution.

Techniques:

Journal: Cancers

Article Title: Machine Learning of Multi-Modal Tumor Imaging Reveals Trajectories of Response to Precision Treatment

doi: 10.3390/cancers15061751

Figure Lengend Snippet: Table summarizing sunitinib treatment responses. Yellow boxes correspond to tumor progression under treatment, n = 10 cases (22.7%), grey boxes correspond to stabilization n = 29 cases (65.9%), and green boxes to tumor regression n = 5 cases (11.3%).

Article Snippet: The sunitinib group received sunitinib malate (Clinisciences, A10880-500) daily at a dose of 50 mg/kg body weight for 6 consecutive weeks, administered by oral gavage of 200 µL in a 10 mg/mL DMSO/PBS (1:4) solution.

Techniques:

Journal: Cancers

Article Title: Machine Learning of Multi-Modal Tumor Imaging Reveals Trajectories of Response to Precision Treatment

doi: 10.3390/cancers15061751

Figure Lengend Snippet: Graphical and tabular representations of the trajectories highlighting the major characteristic features of mice under sunitinib treatment.

Article Snippet: The sunitinib group received sunitinib malate (Clinisciences, A10880-500) daily at a dose of 50 mg/kg body weight for 6 consecutive weeks, administered by oral gavage of 200 µL in a 10 mg/mL DMSO/PBS (1:4) solution.

Techniques:

Journal: bioRxiv

Article Title: Directed evolution of the multicopper oxidase laccase for cell surface proximity labeling and electron microscopy

doi: 10.1101/2024.10.29.620861

Figure Lengend Snippet: ( a ) LaccID labeling in different cell culture media. HEK293T cells expressing surface LaccID were labeled for 2 h with 500 μM BP. ( b ) LaccID labeling with BP versus BMP (biotin-methoxy-phenol). HEK293T cells expressing surface LaccID were labeled for 1 h with 500 μM probe in EBSS. This experiment was performed three times with similar results. ( c ) LaccID comparison to HRP and APEX2 on the surface of HEK293T cells. For LaccID, labeling was performed with 500 μM BP in EBSS or 500 μM BMP in RPMI. For HRP and APEX2, labeling was performed with 500 μM BP and 1 mM H 2 O 2 in DMEM. LaccID molecular weight is 53 kD without glycosylation. ( d ) Confocal imaging of cells labeled as in c . N-cadherin stain is shown as a plasma membrane marker. Neutravidin detects biotinylated proteins. Anti-V5 detects enzyme expression. ( e ) Mutation of the HCH motif (His 450 , Cys 451 , His 452 ) abolishes LaccID activity. HEK293T cells expressing LaccID or mutant LaccID were labelled for 1 h with 500 μM BP in EBSS. This experiment was performed three times with similar results. ( f ) LaccID requires O 2 . HEK293T cells expressing surface LaccID were labeled with 500 μM BP in PBS for 1 h. Glucose oxidase (GOase) and glucose were used to deplete oxygen in the culture media. ( g ) Thermal stability of LacAnc100 and LaccID. Purified enzymes were incubated in citrate-phosphate pH 6.0 buffer at temperatures ranging from 30 to 70 °C, then assayed for activity at pH 4.0 with ABTS substrate. Three technical replicates each; error bars, s.d. ( h ) pH-activity profile for LacAnc100 and LaccID. Purified enzymes were assayed in Britton and Robinson buffer at the indicated pH with the substrate guaiacol. Conversion to product was measured by Abs 470 . Additional data with other substrates (ABTS, 2,6-dimethoxyphenol, p -coumaric acid, and sinapic acid) in Supplementary Figs. 5c-d . ( i ) Kinetic constants for LacAnc100 and LaccID at pH 6.0 with guaiacol. Additional data with other substrates in Supplementary Fig. 5e .

Article Snippet: Next, 180 μL of reaction buffer containing 100 mM citrate-phosphate buffer pH 4.0 and 1 mM ABTS (Panreac, #A1088) as a substrate were added using a Multidrop robot (Multidrop Combi, Thermo Scientific).

Techniques: Labeling, Cell Culture, Expressing, Comparison, Molecular Weight, Imaging, Staining, Membrane, Marker, Mutagenesis, Activity Assay, Purification, Incubation